TNF-alpha: Proteins and Enzymes
TNF-alpha (Tumor necrosis factor alpha) plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism. TNF-alpha was first identified as a cytotoxic factor produced by macrophages capable of killing mouse tumor cells. It is the prototypic ligand and along with Lymphotoxin-alpha, were identified as the first members of the TNF superfamily. Active TNF-alpha and other members of the TNF superfamily exist as a homotrimer with high structural homology. Receptor binding occurs at the interface of two TNF-alpha monomers. And receptor activation occurs when all three monomer interfaces are engaged with a receptor. For TNF-alpha, receptor binding and activation occurs through TNF R1 or TNF RII, and subsequently leads to activation of NF-kB or MAPK signaling pathways. Another pathway that TNF-alpha can activate utilizes the death domain of TNF RI to induce apoptosis. TNF-alpha promotes the inflammatory response largely through NF-kB signaling, and inhibition of TNF-alpha has proven successful in treating many autoimmune disorders. TNF-alpha is also present on the cell surface as membrane-bound TNF-alpha can induce the lysis of neighboring tumor cells and virus infected cells. TNF-alpha protein is translated as a type II transmembrane protein containing an N-terminal transmembrane domain. The soluble cytokine is released from its cell-anchoring TM domain by proteolytic processing by metalloproteases.
21 results for "TNF-alpha Proteins and Enzymes" in Products
Search
Application
Conjugates
Low Endotoxin
Sample Size
Citations
Reviews
TNF-alpha: Proteins and Enzymes
TNF-alpha (Tumor necrosis factor alpha) plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism. TNF-alpha was first identified as a cytotoxic factor produced by macrophages capable of killing mouse tumor cells. It is the prototypic ligand and along with Lymphotoxin-alpha, were identified as the first members of the TNF superfamily. Active TNF-alpha and other members of the TNF superfamily exist as a homotrimer with high structural homology. Receptor binding occurs at the interface of two TNF-alpha monomers. And receptor activation occurs when all three monomer interfaces are engaged with a receptor. For TNF-alpha, receptor binding and activation occurs through TNF R1 or TNF RII, and subsequently leads to activation of NF-kB or MAPK signaling pathways. Another pathway that TNF-alpha can activate utilizes the death domain of TNF RI to induce apoptosis. TNF-alpha promotes the inflammatory response largely through NF-kB signaling, and inhibition of TNF-alpha has proven successful in treating many autoimmune disorders. TNF-alpha is also present on the cell surface as membrane-bound TNF-alpha can induce the lysis of neighboring tumor cells and virus infected cells. TNF-alpha protein is translated as a type II transmembrane protein containing an N-terminal transmembrane domain. The soluble cytokine is released from its cell-anchoring TM domain by proteolytic processing by metalloproteases.
21 results for "TNF-alpha Proteins and Enzymes" in Products
Source : | E. coli |
Accession # : | P06804 |
Applications : | Bioactivity |
Analyzed by SEC-MALS
Source : | HEK293 |
Accession # : | P01375 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P16599 |
Applications : | Bioactivity |
Animal-Free. Earn double rewards for reviews
Source : | E. coli |
Accession # : | P01375.1 |
Applications : | Bioactivity |
Analyzed by SEC-MALS. A new economically priced TNF-alpha is available! The new protein is HEK293 expressed!
Source : | E. coli |
Accession # : | P01375 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P23563 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | Q06599 |
Applications : | Bioactivity |
Intended for preclinical researchers who may transition to GMP TNF-alpha for their clinical work
Source : | E. coli |
Accession # : | P01375.1 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | CAA64403 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | NP_001075288 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P06804 |
Applications : | Bioactivity |
Biotinylated
Source : | CHO |
Accession # : | P01375.1 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P01375 |
Applications : | Enzyme Activity |
Source : | E. coli |
Accession # : | AAL18818 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P48094 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | NP_001272206.1 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P19101 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | NP_001075732 |
Applications : | Bioactivity |
Mutant form with approximately 5-fold greater activity
Source : | E. coli |
Accession # : | P01375 |
Applications : | Bioactivity |
Source : | E. coli |
Accession # : | P51435 |
Applications : | Bioactivity |